Prevention & care

Cervical cancer: HPV, precancer, screening and self-collection, diagnosis, and treatment purposes

8 sources · Latest source check 2026-10-08 UTC

On this page

Cervical cancer begins in the cervix, the lower part of the uterus that connects to the vagina. The main tissue types are squamous cell carcinoma and adenocarcinoma. Precancerous cell changes and invasive cancer are different findings, even when discussed in the same screening pathway.[1]

Different findings need different explanations

Different findings need different explanations
Finding	Meaning
High-risk HPV	A viral infection relevant to cervical-cancer risk.[2]
Precancerous changes	Abnormal cells before invasive cancer develops.[1]
Squamous carcinoma	A cancer arising from squamous cells.[1]
Adenocarcinoma	A cancer arising from glandular cells.[1]

Persistent infection matters more than one positive result

NCI identifies long-lasting high-risk HPV infection as the cause of virtually all cervical cancers. Most HPV infections are controlled by the immune system without progressing to cancer. Persistence can lead to precancerous changes over years; infection, precancer and cancer are not interchangeable stages that everyone inevitably passes through.[2]

Vaccination and screening have complementary purposes

HPV vaccination prevents infections with specified HPV types; it does not treat an existing infection. NCI describes vaccination, screening and timely treatment of relevant abnormalities as complementary prevention measures. Access to follow-up matters alongside having the first test. A preventable disease is not a basis for blaming someone who develops it.[2]

HPV, Pap and co-testing measure different things

An HPV test looks for high-risk virus. A Pap test examines cervical cells for changes. Co-testing combines the two. Screening aims to find relevant changes before symptoms; some cancers are also found. HPV vaccination does not remove the need to follow the appropriate screening framework.[3]

A vaginal HPV sample is not a Pap smear

The current ACS explanation includes clinician-ordered self-collection of a vaginal sample using an authorized device and assay. This can happen in specified clinical or home settings. Pap cytology still uses cervical cells collected by a professional. A positive self-collected HPV result may require a cervical sample and further assessment; avoiding the initial speculum examination does not eliminate all follow-up.[4]

Device authorization has a specific scope

The FDA record for Teal Wand shows a May 2025 De Novo decision for a device used for home collection and transport of vaginal specimens for an approved HPV molecular assay. This does not authorize every online kit or make a home sample a tissue diagnosis. Device, assay, eligibility and follow-up must remain linked.[5]

New bleeding or discharge is not a screening appointment

NCI describes bleeding after sex, bleeding between periods or after menopause, unusual discharge and pelvic pain among possible symptoms. Other conditions can cause these changes, and early cervical cancer may have none. New unexplained changes need assessment; waiting for the next screening invitation is a different pathway from investigating a symptom.[6]

Colposcopy inspects the cervix; biopsy examines tissue

NCI describes colposcopy as magnified examination of the cervix, often with biopsy. Pathology checks tissue for cancer. A loop or cone procedure can obtain tissue and sometimes remove relevant abnormalities. The procedure’s purpose and the pathology result matter; being referred for colposcopy does not mean cancer has already been established.[7]

Staging asks where the cancer has spread

After cancer is established, examination, imaging and selected tests assess extent. This can distinguish disease confined to the cervix from spread nearby or farther away. An HPV type or screening result is not a cancer stage, and the team selects tests for the actual diagnostic question.[7]

Treatments have different local and systemic roles

NCI describes surgery, radiation, chemotherapy, targeted therapy and immunotherapy in appropriate cervical-cancer settings. Brachytherapy places a radiation source within or near the affected area; external radiation delivers radiation from outside. They are distinct procedures, and combination treatment can serve a particular aim rather than indicate duplicated care.[8]

Fertility and organ removal are separate questions to discuss

Some procedures remove cervical tissue; others remove the uterus or additional structures. Removing the uterus and removing the ovaries are different operations. Selected fertility-preserving approaches exist, but suitability depends on cancer findings. Fertility, hormonal function, sexual effects and treatment goals deserve discussion before care begins.[8]

An update is evidence of changed guidance, not universal equivalence

The 2025 ACS update distinguishes intervals and follow-up by collection method. Local pathways and higher-risk settings need their own rules.[4]

Evidence & uncertainty

An abnormal HPV or Pap result is not automatically a cancer diagnosis. The 2025 ACS update includes self-collected vaginal HPV samples, with method-specific rules.[3][4]

Selected-source overview · Independent review pending

Published questions

Does a positive high-risk HPV test mean cervical cancer is present?

Selected-source overview · Independent review pending. Read the evidence context.

Infection and cancer are distinct findings.[2]

Evidence behind this answer

Cervical Cancer Causes, Risk Factors, and Prevention
agency condition or prevention explanation · 2024
Selected relevant original official page passages inspected · Persistent HPV, progression and complementary prevention